Cybin is trading 5.38% lower at $12.32 as broader market weakness pressured biotechnology and growth stocks. - The Nasdaq Composite is down 0.73%, while biotech ETF XBI is down 2.04%. - Higher Treasury yields and inflation concerns are weighing on sentiment. - No clear company-specific negative announcement was identified on September 24, 2026; recent shareholder and clinical-development updates do not directly explain the decline.